Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cephalon Will Buy Generics Firm Mepha

by Lisa M. Jarvis
February 8, 2010 | A version of this story appeared in Volume 88, Issue 6

In a bid to diversify its product offerings, Cephalon will pay roughly $590 million for the Swiss generic drug firm Mepha. Privately held Mepha’s 120 products are marketed in 50 countries and brought in sales of $377 million in 2009. The company has 50 more drugs scheduled for launch by 2015. The deal underscores the pressure on drug companies to find new markets. Although major drugmakers have been pushing into generics and emerging markets in hopes of serving new customers, Cephalon is one of the first biotech firms to make such a move.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.